TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers detailing preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study demonstrated that TTX-MC138 accumulated in metastatic bone lesions after systemic administration, reduced expression of microRNA-10b (miR-10b), and increased expression of the downstream tumor-suppressor target HOXD10, leading to significant survival benefits compared with controls. Repeated dosing was well tolerated with no observed systemic toxicity.
These findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology and suggest potential applicability across additional metastatic disease settings. The results are particularly significant because bone metastasis is a common and serious complication of advanced breast cancer, often leading to skeletal-related events and a poor prognosis. Current treatment options for bone metastases are limited, and there is a high unmet need for therapies that can specifically target metastatic cells.
The study's positive outcomes underscore the potential of TTX-MC138 as a novel therapeutic strategy that could improve outcomes for patients with metastatic breast cancer. By targeting miR-10b, a well-documented biomarker of metastasis, TTX-MC138 aims to disrupt the metastatic process at a molecular level. The accumulation of TTX-MC138 in bone lesions is especially encouraging, as it indicates the drug's ability to reach and act within the metastatic niche.
TransCode's lead candidate is focused on treating metastatic tumors that overexpress miR-10b, and the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The publication of these results in a peer-reviewed journal adds to the growing body of evidence supporting the company's technology platform and its potential to address high-risk cancers.
The implications of this announcement are far-reaching. For patients, the potential for a targeted therapy that can improve survival in metastatic breast cancer represents a significant step forward. For the company, these results could pave the way for further clinical development of TTX-MC138 and strengthen its position in the competitive landscape of oncology therapeutics. Moreover, the findings may have broader implications for other cancers where miR-10b is overexpressed, potentially expanding the therapeutic utility of TTX-MC138 beyond breast cancer.
Investors and stakeholders are likely to view this development positively, as it validates the company's scientific approach and provides tangible evidence of the therapeutic potential of its lead candidate. The full press release can be viewed at https://ibn.fm/E6gbq.
